Guidance toward the implementation of multicriteria decision analysis framework in developing countries

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 18, Issue 6, 2018, Pages 585-592

  Inotai, András ^a,b   Nguyen, Huong Thanh ^c   Hidayat, Budi ^d   Nurgozhin, Talgat ^e   Kiet, Pham Huy Tuan ^f   Campbell, Jonathan D ^g   Németh, Bertalan ^a   Maniadakis, Nikos ^h   Brixner, Diana ⁱ   Wijaya, Kalman ^j   Kaló, Zoltán ^a,b  

^a Syreon Research Institute   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c HANOI UNIVERSITY OF PUBLIC HEALTH   (Viet Nam)

^d UNIVERSITY OF INDONESIA   (Indonesia)

^e ASFENDIYAROV KAZAKH NATIONAL MEDICAL UNIVERSITY   (Kazakhstan)

^f HANOI MEDICAL UNIVERSITY   (Viet Nam)

^g UNIVERSITY OF COLORADO   (United States)

^h NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

ⁱ UNIVERSITY OF UTAH   (United States)

^j Abbott   (Switzerland)

more..

Author keywords

Decision Making; Developing Countries; Implementation Guidance; Multiple Criteria Decision Analysis; Off patent Pharmaceuticals

Indexed keywords

ARTICLE; DECISION MAKING; DEVELOPING COUNTRY; HUMAN; INDONESIA; JOINT; KAZAKHSTAN; PATENT; VIET NAM; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT;

DRUG; GENERIC DRUG;

DECISION MAKING; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; DRUGS, GENERIC; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 85052302223     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2018.1508345     Document Type: Article

References (29)

1. Jindal AK., Universal health coverage: the way forward. Indian J Public Health. 2014;58(3):161–167.
2. Sieleunou I., Health worker migration and universal health care in Sub-Saharan Africa. Pan Afr Med J. 2011;10:55.
3. Peltzer K, Williams JS, Kowal P, et al. Universal health coverage in emerging economies: findings on health care utilization by older adults in China, Ghana, India, Mexico, the Russian Federation, and South Africa. Glob Health Action. 2014;7:25314.
4. Wang YR. The Chinese pharmaceutical market at the crossroads: pro-competition solutions to improve access, quality and affordability. Appl Health Econ Health Policy. 2005;4(3):147–151.
5. Alfonso-Cristancho R, Andia T, Barbosa T, et al. Definition and classification of generic drugs across the world. Appl Health Econ Health Policy. 2015;13(Suppl1):S5–11.
6. Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218–243.
7. Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value trade-offs. Cambridge, UK: Cambridge University Press; 1993.
8. Belton V, Stewart TJ. Multiple criteria decision analysis: an integrated approach. Massachusetts: Kluwer Academic Publishers; 2002.
9. Hu S, Ngorsuraches S, Shen J, et al. Using weighted criteria for making decisions on off-patent medicines: case studies from China, Thailand, And Vietnam. ISPOR 6th Asia-Pacific conference 2014. [cited 2017 Sep 19]. Available from: https://www.ispor.org/Event/GetReleasedPresentation/40
10. Hu S, Zhang Y, He J, et al. A case study of pharmaceutical pricing in China: setting the price for off-patent originators. Appl Health Econ Health Policy. 2015;13(Suppl1):13–20.
11. Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making–an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1–13.
12. Marsh K, IJzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(2):125–137.
13. Kaló Z, Holtorf AP, Alfonso-Cristancho R, et al. Need for multi-criteria evaluation of generic drug policies. Value Health. 2015;18(2):346–351.
14. Brixner D, Maniadakis N, Kaló Z, et al. Applying Multi-Criteria Decision Analysis (MCDA) simple scoring as an evidence-based HTA methodology for evaluating off-patent pharmaceuticals (OPPs) in emerging markets. ViHRI Value Health Reg Issues. 2017;13:1–6.
15. Kaló Z, Inotai A, Wijaya K. Value-based decisions for off-patent pharmaceuticals in developing countries––a pilot study using multi-criteria decision analysis for tenders in Indonesia. Accepted abstract. ISPOR Asia Pacific Conference; 2018 Sep 8–11. Tokyo.
16. Communities and local government. Multi-criteria analysis: a manual. Wetherby: Communities and Local Government Publications; 2009. [cited 2017 Sept19]. Available from: http://eprints.lse.ac.uk/12761/1/Multi-criteria_Analysis.pdf, ISBN: 978-1-4098-1023-0.
17. Sullivan T. Using MCDA (Multi-Criteria Decision Analysis) to prioritise publicly-funded health care. Dunedin: University of Otago; 2012.
18. Development of multiple criteria decision analysis framework for off-patent pharmaceuticals decision making in Vietnam. [cited 2018 May18]. Available from: https://www.eurochamvn.org/node/16937
19. Nurgozhin TS, Nurtayev AI, Maniadakis N. Development of multiple criteria decision analysis framework for off-patent pharmaceuticals procurement in Sk-Pharmacia Kazakhstan. Med (Almaty). 2018;2(188):22–33. [In Russ].
20. Dwiprahasto I, Kristin E, Yasmina A, et al. Development of multiple criteria decision analysis framework for off-patent pharmaceuticals procurement in Indonesia. White paper.
21. Applying Multi-Criteria Decision Analysis (MCDA) simple scoring as evidence-based Health Technology Assessment (HTA) specifically for off-patent pharmaceuticals in emerging markets. ISPOR 20th Annual European Congress. [cited 2018 May21]. Available from: https://www.ispor.org/Event/ReleasedPresentations/2017Glasgow#educationalforum Glasgow.
22. Kolasa K, Kalo Z, Zah V. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):483–488.
23. Radu CP, Chiriac ND, Pravat AM. The development of the Romanian scorecard HTA system. Value Health Reg Issues. 2016;10:41–47.
24. Lopert R, Ruiz F, Chalkidou K. Applying rapid ‘de-facto’ HTA in resource-limited settings: experience from Romania. Health Policy. 2013;112(3):202–208.
25. Horizon 2020. [cited 2018 May18]. Available from: https://ec.europa.eu/programmes/horizon2020/
26. Innovatve medicines initiative. [cited 2018 May18]. Available from: https://www.imi.europa.eu/
27. Brixner D, Kaló Z, Maniadakis N, et al. An Evidence Framework for Off-Patent Pharmaceutical Review (EFOR) for health technology assessment in emerging markets. Value Health Reg Issues. 2018 Mar;29(16):9–13.
28. Inotai A, Petrova G, Vitezic D, et al. Benefits of investment into modern medicines in Central-Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):71–79.
29. Molnár A, Németh B, Inotai A, et al. Comparison of weighting methods used during the construction of multiple-criteria decision analysis tool for repeated use in lower income countries. Value Health 2017;20(9):A776.